

Ahmet Dogan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/754329/publications.pdf>

Version: 2024-02-01

244
papers

11,531
citations

34105

52
h-index

33894

99
g-index

247
all docs

247
docs citations

247
times ranked

13828
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3879-3884.	7.1	853
2	Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood, 2009, 114, 4957-4959.	1.4	746
3	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	1.4	512
4	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood, 2014, 124, 1473-1480.	1.4	401
5	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castlemans disease. Blood, 2017, 129, 1646-1657.	1.4	381
6	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
7	Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2014, 2, 113-122.	4.1	309
8	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery, 2017, 7, 1018-1029.	9.4	302
9	Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood, 2011, 117, 915-919.	1.4	279
10	Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood, 2016, 127, 3004-3014.	1.4	244
11	Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature, 2019, 567, 521-524.	27.8	222
12	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood, 2012, 120, 2280-2289.	1.4	208
13	Hereditary Systemic Amyloidosis Due to Asp76Asn Variant β_2 -Microglobulin. New England Journal of Medicine, 2012, 366, 2276-2283.	27.0	172
14	Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney International, 2012, 82, 226-234.	5.2	166
15	Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?. Blood, 2005, 106, 1501-1502.	1.4	161
16	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	21.4	147
17	Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. Journal of Clinical Pathology, 2006, 60, 361-372.	2.0	144
18	Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica, 2014, 99, 1239-1247.	3.5	140

#	ARTICLE	IF	CITATIONS
19	Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 841-846.	1.0	128
20	Amyloidogenicity and Clinical Phenotype Associated with Five Novel Mutations in Apolipoprotein A-I. <i>American Journal of Pathology</i> , 2011, 179, 1978-1987.	3.8	111
21	Mass Spectrometry-Based Proteomic Diagnosis of Renal Immunoglobulin Heavy Chain Amyloidosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2180-2187.	4.5	109
22	Nodular Pulmonary Amyloidosis Is Characterized by Localized Immunoglobulin Deposition and Is Frequently Associated With an Indolent B-cell Lymphoproliferative Disorder. <i>American Journal of Surgical Pathology</i> , 2013, 37, 406-412.	3.7	105
23	Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. <i>Laboratory Investigation</i> , 2008, 88, 1024-1037.	3.7	103
24	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 440-459.	9.4	103
25	The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. <i>Modern Pathology</i> , 2018, 31, 581-597.	5.5	102
26	Mass Spectrometric-Based Proteomic Analysis of Amyloid Neuropathy Type in Nerve Tissue. <i>Archives of Neurology</i> , 2011, 68, 195-9.	4.5	101
27	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. <i>Blood</i> , 2017, 129, 299-306.	1.4	99
28	The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 259-275.	2.8	97
29	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	1.6	97
30	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	6.2	96
31	A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. <i>Journal of Clinical Pathology</i> , 2015, 68, 314-317.	2.0	95
32	Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM. <i>Blood</i> , 2017, 130, 742-742.	1.4	92
33	MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. <i>Blood Advances</i> , 2017, 1, 728-732.	5.2	84
34	Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. <i>Kidney International</i> , 2014, 86, 370-377.	5.2	82
35	Revealing the Impact of Structural Variants in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2020, 1, 258-273.	5.0	81
36	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <i>Nature Communications</i> , 2018, 9, 2024.	12.8	80

#	ARTICLE	IF	CITATIONS
37	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. <i>Blood Cancer Journal</i> , 2019, 9, 50.	6.2	75
38	Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 71-75.	3.0	74
39	Amyloidosis: Insights from Proteomics. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 277-304.	22.4	72
40	An ethnobotanical study of medicinal plants in Acipayam (Denizli-Turkey). <i>Journal of Herbal Medicine</i> , 2017, 10, 64-81.	2.0	72
41	Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. <i>Blood</i> , 2018, 132, 959-959.	1.4	71
42	Leukocyte cell-derived chemotaxin 2 (LECT2)â€“associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. <i>Blood</i> , 2014, 123, 1479-1482.	1.4	70
43	Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 330-342.	2.8	69
44	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-Î² positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	1.4	68
45	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. <i>Nature Communications</i> , 2021, 12, 1861.	12.8	68
46	Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. <i>Blood</i> , 2019, 134, 678-687.	1.4	65
47	A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. <i>Blood</i> , 2021, 138, 2828-2837.	1.4	65
48	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	7.1	63
49	Strong Transthyretin Immunostaining. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1685-1690.	3.7	62
50	Shotgunâ€“proteomicsâ€“based clinical testing for diagnosis and classification of amyloidosis. <i>Journal of Mass Spectrometry</i> , 2013, 48, 1067-1077.	1.6	62
51	Leukocyte Cellâ€“Derived Chemotaxin 2â€“Associated Amyloidosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2084-2093.	4.5	61
52	Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. <i>Blood Advances</i> , 2020, 4, 2261-2271.	5.2	61
53	Crystalâ€“storing histiocytosis: a clinicopathological study of 13 cases. <i>Histopathology</i> , 2016, 68, 482-491.	2.9	60
54	Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. <i>Cancer Discovery</i> , 2019, 9, 1452-1467.	9.4	60

#	ARTICLE	IF	CITATIONS
55	CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 626-635.	1.4	59
56	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	12.8	58
57	T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 285-308.	4.9	58
58	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. <i>JAMA Oncology</i> , 2019, 5, 1293.	7.1	57
59	Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders. <i>Modern Pathology</i> , 2013, 26, 232-238.	5.5	56
60	Relationship between monoclonal gammopathy and cardiac amyloid type. <i>Cardiovascular Pathology</i> , 2013, 22, 189-194.	1.6	52
61	Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA–NCI roundtable symposium. <i>American Journal of Hematology</i> , 2014, 89, 1159-1160.	4.1	52
62	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	2.9	52
63	Plasmacytoid dendritic cell expansion defines a distinct subset of <i>RUNX1</i> -mutated acute myeloid leukemia. <i>Blood</i> , 2021, 137, 1377-1391.	1.4	51
64	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	2.1	51
65	Proteomic Detection of Immunoglobulin Light Chain Variable Region Peptides from Amyloidosis Patient Biopsies. <i>Journal of Proteome Research</i> , 2015, 14, 1957-1967.	3.7	50
66	D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. <i>Nature Communications</i> , 2016, 7, 10353.	12.8	50
67	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432.	4.6	50
68	T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4640-4647.	5.2	50
69	Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. <i>Histopathology</i> , 2016, 68, 648-656.	2.9	48
70	Renal Amyloidosis Associated With a Novel Sequence Variant of Gelsolin. <i>American Journal of Kidney Diseases</i> , 2013, 61, 161-166.	1.9	47
71	Breast Implant-associated Anaplastic Large Cell Lymphoma Incidence. <i>Annals of Surgery</i> , 2020, 272, 403-409.	4.2	47
72	Pitfalls in the Diagnosis of Primary Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 177-180.	0.4	46

#	ARTICLE	IF	CITATIONS
73	Recurrent somatic JAK3 mutations in NK-cell enteropathy. <i>Blood</i> , 2019, 134, 986-991.	1.4	42
74	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. <i>Oncotarget</i> , 2015, 6, 9488-9501.	1.8	42
75	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.	12.8	41
76	Clinical Proteome Informatics Workbench Detects Pathogenic Mutations in Hereditary Amyloidoses. <i>Journal of Proteome Research</i> , 2014, 13, 2352-2358.	3.7	40
77	Single-agent dabrafenib for <i>BRAF</i> ^{V600E} -mutated histiocytosis. <i>Haematologica</i> , 2018, 103, e177-e180.	3.5	40
78	New insights into the in vitro biological effects, in silico docking and chemical profile of clary sage “ <i>Salvia sclarea</i> L.. <i>Computational Biology and Chemistry</i> , 2018, 75, 111-119.	2.3	40
79	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 101.	6.2	40
80	Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster. <i>JAMA Oncology</i> , 2018, 4, 821.	7.1	38
81	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	1.4	38
82	Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma. <i>American Journal of Clinical Pathology</i> , 2016, 146, 41-49.	0.7	37
83	B-cell maturation antigen expression across hematologic cancers: a systematic literature review. <i>Blood Cancer Journal</i> , 2020, 10, 73.	6.2	36
84	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. <i>Blood Advances</i> , 2019, 3, 2487-2490.	5.2	35
85	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. <i>Nature Cancer</i> , 2020, 1, 653-664.	13.2	35
86	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
87	Localized insulin-derived amyloidosis: A potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. <i>American Journal of Hematology</i> , 2012, 87, E131-2.	4.1	34
88	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . <i>Haematologica</i> , 2020, 105, e5-e8.	3.5	34
89	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 862-862.	1.4	34
90	Globular Hepatic Amyloid Is Highly Sensitive and Specific for LECT2 Amyloidosis. <i>American Journal of Surgical Pathology</i> , 2015, 39, 558-564.	3.7	33

#	ARTICLE	IF	CITATIONS
91	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 87-97.	2.1	32
92	Pioneers of Breast Implant-Associated Anaplastic Large Cell Lymphoma: History from Case Report to Global Recognition. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 7S-14S.	1.4	31
93	Immunohistochemical Detection of $\text{CD}3/\text{T}$ Lymphocytes in Formalin-fixed Paraffin-embedded Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 581-583.	1.2	31
94	Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. <i>Neuro-Oncology</i> , 2020, 22, 979-992.	1.2	31
95	The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2012, 120, 2700-2700.	1.4	31
96	Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel <i>STAT3/JAK2</i> fusion among other activating genetic alterations within the <i>JAK/STAT</i> pathway. <i>Breast Journal</i> , 2021, 27, 314-321.	1.0	29
97	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. <i>Journal of Clinical Investigation</i> , 2020, 130, 6668-6676.	8.2	28
98	The Combination of Duvelisib, a PI3K- γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts. <i>Blood</i> , 2018, 132, 683-683.	1.4	28
99	Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. <i>Nature Communications</i> , 2021, 12, 5172.	12.8	27
100	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	6.2	25
101	T-cell receptor γ expression and $\text{CD}3^+$ T-cell infiltrates in primary cutaneous $\text{CD}3^+$ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. <i>Histopathology</i> , 2018, 73, 653-662.	2.9	24
102	Fibrinogen alpha amyloidosis: insights from proteomics. <i>Expert Review of Proteomics</i> , 2019, 16, 783-793.	3.0	24
103	<i>Paeonia arietina</i> and <i>Paeonia kesrounensis</i> bioactive constituents: NMR, LC-DAD-MS fingerprinting and in vitro assays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 165, 1-11.	2.8	24
104	[^{18}F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients. <i>Cancers</i> , 2020, 12, 1138.	3.7	24
105	Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 901-911.	2.8	22
106	Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. <i>Blood Advances</i> , 2020, 4, 1812-1823.	5.2	22
107	Wild Edible Plants of Pertek (Tunceli-Turkey). <i>Marmara Pharmaceutical Journal</i> , 2015, 2, 126-126.	0.5	21
108	Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center. <i>Breast Journal</i> , 2019, 25, 69-74.	1.0	21

#	ARTICLE	IF	CITATIONS
109	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2991-2991.	1.4	21
110	Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 705-719.	2.2	20
111	Bioactivities of <i>Achillea phrygia</i> and <i>Bupleurum croceum</i> based on the composition of phenolic compounds: In vitro and in silico approaches. <i>Food and Chemical Toxicology</i> , 2017, 107, 597-608.	3.6	20
112	Biologically active compounds from two members of the Asteraceae family: <i>Tragopogon dubius</i> Scop. and <i>Tussilago farfara</i> L.. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 3269-3281.	3.5	20
113	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4019-4019.	1.4	20
114	Experimental and numerical investigation of drainage mechanisms at sports fields under simulated rainfall. <i>Journal of Hydrology</i> , 2020, 580, 124251.	5.4	19
115	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 181-199.	2.8	19
116	Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. <i>American Journal of Hematology</i> , 2013, 88, 577-580.	4.1	18
117	Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, e163-e166.	3.5	17
118	Involved-site radiotherapy for <i>Helicobacter pylori</i> -independent gastric MALT lymphoma: 26 years of experience with 178 patients. <i>Blood Advances</i> , 2021, 5, 1830-1836.	5.2	17
119	Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. <i>JCI Insight</i> , 2019, 4, .	5.0	17
120	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	2.7	15
121	Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. <i>Blood</i> , 2011, 118, 1570-1570.	1.4	15
122	Genetic basis for iMCD-TAFRO. <i>Oncogene</i> , 2020, 39, 3218-3225.	5.9	14
123	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	2.5	13
124	Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma. <i>Surgical Pathology Clinics</i> , 2019, 12, 699-707.	1.7	13
125	Incidence of benign and malignant peri-implant fluid collections and masses on magnetic resonance imaging in women with silicone implants. <i>Cancer Medicine</i> , 2020, 9, 3261-3267.	2.8	13
126	Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases. <i>Blood</i> , 2013, 122, 1900-1900.	1.4	13

#	ARTICLE	IF	CITATIONS
127	HPLC-MS/MS-based metabolic profiling and pharmacological properties of extracts and infusion obtained from <i>Amelanchier parviflora</i> var. <i>dentata</i> . <i>Industrial Crops and Products</i> , 2018, 124, 699-706.	5.2	12
128	<i>In Vitro</i> , <i>In Vivo</i> , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K- δ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2017, 130, 819-819.	1.4	12
129	Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. <i>Oncotarget</i> , 2017, 8, 103274-103282.	1.8	12
130	Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma. <i>Journal of Hematopathology</i> , 2015, 8, 235-241.	0.4	11
131	Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis. <i>Haematologica</i> , 2018, 103, e610-e612.	3.5	11
132	14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 509-518.	1.5	11
133	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020, 12, 1603.	3.7	11
134	Immune independent crosstalk between lymphoma and myeloid suppressor CD14 ⁺ HLA-DR ^{low/neg} monocytes mediates chemotherapy resistance. <i>Oncolmmunology</i> , 2015, 4, e996470.	4.6	10
135	Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 204-208.	2.0	10
136	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3382-3390.	5.2	10
137	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2010, 116, 140-140.	1.4	10
138	CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2022, 63, 751-754.	1.3	10
139	Advances in clinical applications of tissue proteomics: opportunities and challenges. <i>Expert Review of Proteomics</i> , 2014, 11, 531-533.	3.0	9
140	<i>FCGR3A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	1.7	9
141	Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 32.	6.2	9
142	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. <i>Blood</i> , 2019, 134, 1619-1619.	1.4	9
143	Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. <i>Modern Pathology</i> , 2018, 31, 881-889.	5.5	8
144	Rainfall simulator for investigating sports field drainage processes. <i>Measurement: Journal of the International Measurement Confederation</i> , 2018, 125, 360-370.	5.0	8

#	ARTICLE	IF	CITATIONS
145	Peripheral T-cell lymphoma “ are we making progress?. Best Practice and Research in Clinical Haematology, 2018, 31, 306-314.	1.7	8
146	Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma. Journal of Physical Education and Sports Management, 2019, 5, a004259.	1.2	8
147	Chemical composition and biological activities of endemic <i>Tripleurospermum conoclinium</i> (Boiss. & Balansa) Hayek essential oils. Flavour and Fragrance Journal, 2020, 35, 713-721.	2.6	8
148	Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition. Haematologica, 2021, 106, 614-618.	3.5	8
149	Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.. Blood, 2005, 106, 938-938.	1.4	8
150	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood, 2022, 140, 1822-1826.	1.4	8
151	Phenolic components and assessment of biological properties of <i>Tchihatchewia isatidea</i> Boiss. extracts: Docking and functional approaches for designing novel products. Food and Chemical Toxicology, 2018, 111, 423-431.	3.6	7
152	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Modern Pathology, 2021, 34, 2183-2191.	5.5	7
153	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution. Blood, 2019, 134, 22-22.	1.4	7
154	A Case of Insulin Resistance Secondary to Insulin Induced Localized Cutaneous Amyloidosis.. Blood, 2009, 114, 4908-4908.	1.4	7
155	Acute myeloid leukemia masquerading as hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2016, 7, E31-E35.	1.4	6
156	Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow. Journal of Hematopathology, 2016, 9, 9-18.	0.4	6
157	Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features. Blood Cancer Journal, 2020, 10, 116.	6.2	6
158	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. Blood, 2012, 120, 1545-1545.	1.4	6
159	Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant <i>De Novo</i> Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor. Journal of Hematology (Brossard, Quebec), 2020, 9, 140-146.	1.0	6
160	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. Blood, 2020, 136, 11-12.	1.4	6
161	Chemical Composition, Anti-Inflammatory, Antioxidant and Antimicrobial Activity of Essential Oil from Aerial Parts of <i>Chaerophyllum aromaticum</i> L. from Turkey. Journal of Essential Oil-bearing Plants: JEOP, 2018, 21, 563-569.	1.9	5
162	Histiocytic sarcoma arising in patient with history of clonally related germ cell tumour and myelodysplastic syndrome. British Journal of Haematology, 2020, 188, 482-482.	2.5	5

#	ARTICLE	IF	CITATIONS
163	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. <i>Clinical Cancer Research</i> , 2021, 27, 2111-2118.	7.0	5
164	First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5452-5452.	1.4	5
165	Romidepsin activity in T follicular helper(TFH)-phenotype PTCL versus non TFH treated on the same clinical trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7509-7509.	1.6	5
166	PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 189-198.	1.5	5
167	Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2017, 58, 2962-2965.	1.3	4
168	Hairy cell leukemia expresses programmed death-1. <i>Blood Cancer Journal</i> , 2020, 10, 115.	6.2	4
169	Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 1785-1785.	1.4	4
170	Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome. <i>HemaSphere</i> , 2022, 6, e685.	2.7	4
171	The Expanding Spectrum of Follicular Lymphoma. <i>Surgical Pathology Clinics</i> , 2016, 9, 29-40.	1.7	3
172	Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of BRAF V600E Testing in Diagnosis and Treatment. <i>JCO Precision Oncology</i> , 2021, 5, 1035-1039.	3.0	3
173	A Clinical Test for the Identification of Amyloid Proteins in Biopsy Specimens by a Novel Method Based on Laser Microdissection and Mass Spectrometry.. <i>Blood</i> , 2007, 110, 1480-1480.	1.4	3
174	Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target.. <i>Blood</i> , 2007, 110, 690-690.	1.4	3
175	ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature. <i>Blood</i> , 2011, 118, 88-88.	1.4	3
176	MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.. <i>Blood</i> , 2012, 120, 2699-2699.	1.4	3
177	Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform. <i>Blood</i> , 2013, 122, 1761-1761.	1.4	3
178	Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses. <i>Blood</i> , 2016, 128, 951-951.	1.4	3
179	Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase. <i>Blood</i> , 2019, 134, 2148-2148.	1.4	3
180	Seroma-associated anaplastic large-cell lymphoma arising on the background of subcutaneous calcinosis: beyond breast implants. <i>Histopathology</i> , 2016, 69, 890-892.	2.9	2

#	ARTICLE	IF	CITATIONS
181	<i>FGFR1</i> Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia. JCO Precision Oncology, 2020, 4, 937-943.	3.0	2
182	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 3127-3127.	1.4	2
183	Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive <i>Versus</i> Stable Myeloma Precursor Disease. Blood, 2020, 136, 47-48.	1.4	2
184	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. Blood, 2020, 136, 50-51.	1.4	2
185	Diagnosis and Classification of Amyloidosis in Abdominal Subcutaneous Fat Aspiration Specimens Using Mass Spectrometry Based Proteomics. Blood, 2008, 112, 2710-2710.	1.4	2
186	A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).. Blood, 2012, 120, 2687-2687.	1.4	2
187	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. Blood, 2013, 122, 499-499.	1.4	2
188	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers, 2021, 13, 5502.	3.7	2
189	TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy. Blood, 2021, 138, 1367-1367.	1.4	2
190	Quantitative Off-Target Detection of Epstein-Barr Virusâ€Derived DNA in Routine Molecular Profiling of Hematopoietic Neoplasms by Panel-Based Hybrid-Capture Next-Generation Sequencing. Journal of Molecular Diagnostics, 2021, , .	2.8	2
191	Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 52-53.	1.4	2
192	Abnormal Bâ€Lymphoblasts in myelodysplastic syndromes and myeloproliferative neoplasms other than chronic myeloid leukemia. Cytometry Part B - Clinical Cytometry, 2021, , .	1.5	2
193	First report of bilateral breast-implant associated anaplastic large cell lymphoma caused by identical T-cell clone. Leukemia and Lymphoma, 2022, 63, 2747-2750.	1.3	2
194	Diagnosis of Nodal Peripheral T-Cell Lymphomas. Surgical Pathology Clinics, 2010, 3, 955-988.	1.7	1
195	Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometryâ€based proteomics in an Australian cohort.. Internal Medicine Journal, 2020, , .	0.8	1
196	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. JCO Precision Oncology, 2020, 4, 1280-1284.	3.0	1
197	Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma. Blood, 2018, 132, 2880-2880.	1.4	1
198	Renal Heavy Chain and Heavy+Light Chain Amyloidosis: A Report of 17 Cases and Comparison with Renal Light Chain Amyloidosis. Blood, 2012, 120, 3992-3992.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Clarifying immunoglobulin gene usage in immunoglobulin light chain amyloidosis by mass spectrometry of amyloid in clinical tissue specimens.. Journal of Clinical Oncology, 2014, 32, 8605-8605.	1.6	1
200	Angioimmunoblastic T-Cell Lymphoma: A Large Series Outcome Analysis.. Blood, 2005, 106, 2810-2810.	1.4	1
201	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. Blood, 2009, 114, 3933-3933.	1.4	1
202	Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription.. Blood, 2009, 114, 3927-3927.	1.4	1
203	Massively Parallel Mate Pair DNA Library Sequencing for Translocation Discovery: Recurrent t(6;7)(p25.3;q32.3) Translocations In ALK-Negative Anaplastic Large Cell Lymphomas. Blood, 2010, 116, 633-633.	1.4	1
204	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (ã~) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. Blood, 2012, 120, 1604-1604.	1.4	1
205	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	1.4	1
206	Activation Of TAK1 By MYD88 L265P Drives Malignant B Cell Growth In Non-Hodgkin Lymphomas. Blood, 2013, 122, 245-245.	1.4	1
207	High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma. Blood, 2015, 126, 1485-1485.	1.4	1
208	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 3655-3655.	1.4	1
209	Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis. Blood, 2018, 132, 1624-1624.	1.4	1
210	Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience. Blood, 2019, 134, 2850-2850.	1.4	1
211	Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms. Blood, 2019, 134, 3978-3978.	1.4	1
212	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 7-7.	1.4	1
213	The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data. Blood, 2020, 136, 10-10.	1.4	1
214	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer Journal, 2022, 12, 29.	6.2	1
215	Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives of Pathology and Laboratory Medicine, 2023, 147, 79-86.	2.5	1
216	Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications. Leukemia and Lymphoma, 2020, 61, 460-464.	1.3	0

#	ARTICLE	IF	CITATIONS
217	Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. Bone Marrow Transplantation, 2020, 55, 2331-2334.	2.4	0
218	Gene Expression Profiling of Post-Follicular B-Cell Lymphoma. Blood, 2008, 112, 617-617.	1.4	0
219	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras.. Blood, 2009, 114, 443-443.	1.4	0
220	A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. Blood, 2010, 116, 1999-1999.	1.4	0
221	Proteomic Analysis of Immunoglobulin Light Chains (LC) In AL Amyloidosis Shows That the Sequence of Clonal LC Secreted by the Neoplastic Plasma Cells Is Identical to the LC Deposited In the Amyloid Plaques. Blood, 2010, 116, 1909-1909.	1.4	0
222	Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation. Blood, 2011, 118, 960-960.	1.4	0
223	Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?. Blood, 2011, 118, 2638-2638.	1.4	0
224	Silencing of SHP1 Is Frequent in Phospho-STAT3 Positive Diffuse Large Cell Lymphoma and This Silencing Is Independent of Methylation of CpG Islands,. Blood, 2011, 118, 3678-3678.	1.4	0
225	The Mutational Landscape of Diffuse Large B Cell Lymphoma. Blood, 2011, 118, 259-259.	1.4	0
226	Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP. Blood, 2012, 120, 1575-1575.	1.4	0
227	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1534-1534.	1.4	0
228	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. Blood, 2012, 120, 149-149.	1.4	0
229	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. Blood, 2012, 120, 1563-1563.	1.4	0
230	Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.. Blood, 2012, 120, 2655-2655.	1.4	0
231	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. Blood, 2012, 120, 3637-3637.	1.4	0
232	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. Blood, 2012, 120, 2702-2702.	1.4	0
233	Deep Proteomic Profiling Predicts Differential Chemosensitivity In Anaplastic Large Cell Lymphoma Cell Lines. Blood, 2013, 122, 1670-1670.	1.4	0
234	Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis. Blood, 2013, 122, 3142-3142.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Blood</i> , 2015, 126, 481-481.	1.4	0
236	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. <i>Blood</i> , 2015, 126, 2668-2668.	1.4	0
237	Association of MHC-II, PD-L1, and FoxP3 with Disease Status and Outcomes in Patients with Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1774-1774.	1.4	0
238	Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term. <i>Blood</i> , 2019, 134, 2842-2842.	1.4	0
239	CD4 Lymphocytes and T Regulatory Cells Show Distinct Phenotypes in Follicular Lymphoma and Classical Hodgkin Lymphoma Which May Account for Differences in Responses to Checkpoint Therapy. <i>Blood</i> , 2019, 134, 1513-1513.	1.4	0
240	Transformation of monoclonal B lymphocytosis to Epstein-Barr virus-positive large B-cell lymphoma with intermediate features between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. <i>AJSP Review and Reports</i> , 2019, 24, 207-211.	0.1	0
241	The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. <i>Blood</i> , 2021, 138, 2394-2394.	1.4	0
242	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
243	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. <i>Blood</i> , 2020, 136, 50-51.	1.4	0
244	Clinical Characteristics and Follow-up Post-Surgery of Women with Bia-ALCL Operated at a Single Institution. <i>Blood</i> , 2020, 136, 32-33.	1.4	0